ArticleMovement disorders : official journal of the Movement Disorder Society2022
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Pallidal Volumetry and Neutrophil-to-Lymphocyte Ratio in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease.Diseases (Basel, Switzerland) · 2026Article
- Patterns of iron deposition and classification in parkinsonian syndromes: a quantitative susceptibility mapping study.Journal of neurology · 2026Article
- Article
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.Frontiers in aging neuroscience · 2026Review
- From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.Frontiers in aging neuroscience · 2026Review
- Automated MRI-Based Classification of Parkinsonism: A Deep Learning Approach to Distinguish PD From PSP.CNS neuroscience & therapeutics · 2025Article
- Review
- Annual percentage change of MR Parkinsonism index in progressive supranuclear palsy: a feasibility study.European radiology · 2025Article
- Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.Diagnostics (Basel, Switzerland) · 2025Article
- Brainstem and cerebellar radiological findings in progressive supranuclear palsy.Brain communications · 2025Review
- Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.International journal of molecular sciences · 2024Review
- Systematic assessment of square-wave jerks in progressive supranuclear palsy: a video-oculographic study.Journal of neurology · 2024Article
- Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Deep Learning-based Approach for Brainstem and Ventricular MR Planimetry: Application in Patients with Progressive Supranuclear Palsy.Radiology. Artificial intelligence · 2024Article
- A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism.Movement disorders clinical practice · 2024Article
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Simple biomarkers to distinguish Parkinson's disease from its mimics in clinical practice: a comprehensive review and future directions.Frontiers in neurology · 2024Review
- Planimetric and Volumetric Brainstem MRI Markers in Progressive Supranuclear Palsy, Multiple System Atrophy, and Corticobasal Syndrome. A Systematic Review and Meta-Analysis.Neurology international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) is clinically challenging.
objectiveThis study aimed to develop an automated Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0) algorithm to distinguish PSP-P from PD and to validate its diagnostic performance in two large independent cohorts.
methodsWe enrolled 676 participants: a training cohort (n = 346; 43 PSP-P, 194 PD, and 109 control subjects) from our center and an independent testing cohort (n = 330; 62 PSP-P, 171 PD, and 97 control subjects) from an international research group. We developed a new in-house algorithm for MRPI 2.0 calculation and assessed its performance in distinguishing PSP-P from PD and control subjects in both cohorts using receiver operating characteristic curves.
resultsThe automated MRPI 2.0 showed excellent performance in differentiating patients with PSP-P from patients with PD and control subjects both in the training cohort (area under the receiver operating characteristic curve [AUC] = 0.93 [95% confidence interval, 0.89-0.98] and AUC = 0.97 [0.93-1.00], respectively) and in the international testing cohort (PSP-P versus PD, AUC = 0.92 [0.87-0.97]; PSP-P versus controls, AUC = 0.94 [0.90-0.98]), suggesting the generalizability of the results. The automated MRPI 2.0 also accurately distinguished between PSP-P and PD in the early stage of the diseases (AUC = 0.91 [0.84-0.97]). A strong correlation (r = 0.91, P < 0.001) was found between automated and manual MRPI 2.0 values.
conclusionsOur study provides an automated, validated, and generalizable magnetic resonance biomarker to distinguish PSP-P from PD. The use of the automated MRPI 2.0 algorithm rather than manual measurements could be important to standardize measures in patients with PSP-P across centers, with a positive impact on multicenter studies and clinical trials involving patients from different geographic regions. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.